![](https://i.kinja-img.com/image/upload/c_fit,q_80,w_636/fa0dc338433d04140ad32fa9dea3f418.jpg)
AstraZeneca, the UK-based maker of popular inhalers like Symbicort and Airsupra, announced Monday it plans to cap costs for patients using its inhalers in the U.S. at $35 per month starting June 1.
AstraZeneca, the UK-based maker of popular inhalers like Symbicort and Airsupra, announced Monday it plans to cap costs for patients using its inhalers in the U.S. at $35 per month starting June 1.
AstraZeneca submitted a request for the FDA on Wednesday to approve a self-administered nasal flu vaccine for people ages two to 49 years old.